These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 8855830)

  • 21. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
    Worm D; Henriksen JE; Vaag A; Thye-Rønn P; Melander A; Beck-Nielsen H
    J Clin Endocrinol Metab; 1994 Mar; 78(3):717-21. PubMed ID: 8126147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of 6 months' gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial CSII-induced normoglycemia.
    Della Casa L; del Rio G; Glaser B; Cerasi E
    Diabetes Res Clin Pract; 1991; 14 Suppl 2():S69-78. PubMed ID: 1794269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.
    Eliasson B; Gudbjörnsdottir S; Cederholm J; Liang Y; Vercruysse F; Smith U
    Int J Obes (Lond); 2007 Jul; 31(7):1140-7. PubMed ID: 17264849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The treatment of the obese non-insulin-dependent patient with d-fenfluramine].
    Daniele E; Coco MP
    Clin Ter; 1996 Apr; 147(4):199-204. PubMed ID: 8766352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High plasma free fatty acids decrease splanchnic glucose uptake in patients with non-insulin-dependent diabetes mellitus.
    Tomita T; Yamasaki Y; Kubota M; Tohdo R; Katsura M; Ikeda M; Nakahara I; Shiba Y; Matsuhisa M; Hori M
    Endocr J; 1998 Apr; 45(2):165-73. PubMed ID: 9700469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic induction of weight loss to treat type 2 diabetes.
    Redmon JB; Raatz SK; Kwong CA; Swanson JE; Thomas W; Bantle JP
    Diabetes Care; 1999 Jun; 22(6):896-903. PubMed ID: 10372238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benfluorex action on metabolic control and insulin sensitivity in type 2 non-insulin dependent diabetics.
    Pasquali R; Colella P; Capelli M; Zannarini L; Melchionda N; Barbara L
    Panminerva Med; 1989; 31(3):114-8. PubMed ID: 2689969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin.
    Damsbo P; Hermann LS; Vaag A; Hother-Nielsen O; Beck-Nielsen H
    Diabetes Care; 1998 Sep; 21(9):1489-94. PubMed ID: 9727896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial].
    Tong NW; Ran XW; Li QF; Tang BD; Li R; Yang FY; Liu YP; Li XJ
    Zhonghua Nei Ke Za Zhi; 2005 Sep; 44(9):659-63. PubMed ID: 16202254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control.
    Gokcel A; Karakose H; Ertorer EM; Tanaci N; Tutuncu NB; Guvener N
    Diabetes Care; 2001 Nov; 24(11):1957-60. PubMed ID: 11679464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.
    Paolisso G; Tagliamonte MR; Rizzo MR; Gualdiero P; Saccomanno F; Gambardella A; Giugliano D; D'Onofrio F; Howard BV
    Diabetologia; 1998 Oct; 41(10):1127-32. PubMed ID: 9794097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secretion and hepatic extraction of insulin after weight loss in obese noninsulin-dependent diabetes mellitus.
    Henry RR; Brechtel G; Griver K
    J Clin Endocrinol Metab; 1988 May; 66(5):979-86. PubMed ID: 3283164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
    Juhl CB; Pørksen N; Pincus SM; Hansen AP; Veldhuis JD; Schmitz O
    Diabetes; 2001 Aug; 50(8):1778-84. PubMed ID: 11473038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contribution of obesity to insulin resistance in noninsulin-dependent diabetes mellitus.
    Perriello G; Misericordia P; Volpi E; Pampanelli S; Santeusanio F; Brunetti P; Bolli GB
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2464-9. PubMed ID: 7629243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carbohydrate tolerance improves with fasting in obese subjects with noninsulin-dependent (type II) diabetes.
    Watts NB; DiGirolamo M
    Am J Med Sci; 1990 Apr; 299(4):250-6. PubMed ID: 2181873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus.
    Kelley DE; Wing R; Buonocore C; Sturis J; Polonsky K; Fitzsimmons M
    J Clin Endocrinol Metab; 1993 Nov; 77(5):1287-93. PubMed ID: 8077323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects.
    Fulcher GR; Walker M; Catalano C; Agius L; Alberti KG
    Diabetes; 1992 Nov; 41(11):1400-8. PubMed ID: 1397716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.